Search results for Afutuzumab ELISA Kit
Afutuzumab ELISA Kit, ProteoGenix, KPTX293
Description of Afutuzumab ELISA Kit Introduction Afutuzumab is a monoclonal antibody that has been developed as a potential therapeutic target for various types of cancer. It specifically targets the CD20 protein, which is found on the surface of B-cells. Afutuzumab has shown promising results in preclinical studies, and its potential as a cancer treatment has led to the development of an Afutuzumab ELISA Kit. Structure of Afutuzumab Afutuzumab is a humanized IgG1 monoclonal antibody, meaning that it is derived from human antibodies but has been modified to increase its therapeutic potential. It consists of two heavy chains and two light chains, which are connected by disulfide bonds. The variable regions of the antibody are responsible for binding to the CD20 protein, while the constant regions determine the effector functions of the antibody. The structure of Afutuzumab has been carefully designed to maximize its specificity and efficacy. Its binding site has been engineered to target a unique epitope on the CD20 protein, which is not shared by other antibodies targeting the same protein. This allows for a more precise and targeted approach in cancer treatment. Activity of Afutuzumab Afutuzumab works by binding to the CD20 protein on the surface of B-cells, leading to their destruction through various mechanisms. One of the mechanisms is antibody-dependent cellular cytotoxicity (ADCC), where the bound antibody activates immune cells to attack and kill the cancerous B-cells. Another mechanism is antibody-dependent cellular phagocytosis (ADCP), where the bound antibody marks the cancer cells for destruction by macrophages. In addition to its direct effects on B-cells, Afutuzumab also has indirect effects on the tumor microenvironment. It has been shown to inhibit the growth of new blood vessels, which are necessary for tumor growth and metastasis. It also activates the immune system, leading to a more robust and sustained anti-tumor response. Application of Afutuzumab ELISA Kit The Afutuzumab ELISA Kit is a valuable tool for researchers studying the efficacy and mechanism of action of Afutuzumab. It can be used to measure the levels of Afutuzumab in biological samples, such as serum or plasma, to determine the pharmacokinetics of the antibody. This information is crucial in determining the appropriate dosage and dosing schedule for patients. The kit can also be used to measure the levels of CD20 protein in biological samples, which can help in predicting the response to Afutuzumab treatment. It can also be used to monitor the levels of CD20 during treatment, as a decrease in CD20 levels may indicate a positive response to the therapy. In addition, the Afutuzumab ELISA Kit can be used to screen for potential biomarkers that may be associated with response or resistance to Afutuzumab treatment. This can aid in identifying patients who are most likely to benefit from the therapy, as well as in the development of personalized treatment approaches. Conclusion In conclusion, Afutuzumab is a promising therapeutic target for cancer treatment, and the development of the Afutuzumab ELISA Kit has facilitated its further research and application. The precise structure and activity of Afutuzumab make it a highly specific and effective treatment option for various types of cancer. With ongoing research and clinical trials, Afutuzumab has the potential to significantly improve outcomes for cancer patients.
Host
Reactivity
Applications
Conjugation
Afutuzumab ELISA Kit, Abbexa, abx395063
Afutuzumab ELISA Kit is a quantitative ELISA kit for detection of Afutuzumab.Afutuzumab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes. Upon binding to CD20, obinutuzumab mediates B-cell lysisthrough (1) engagement of immune effector cells (2) by directly activating intracellular death signaling pathways (direct cell death), and/or (3) activation of the complement cascade. The immune effector cell mechanisms include antibody-dependent cellular cytotoxicity (ADCC) and antibodydependent cellular phagocytosis.As an antibody with reduced fucose content, obinutuzumab induces greater ADCC activity than rituximab in vitro using human cancer cell lines. Afutuzumab also demonstrated an increased ability to induce direct cell death when compared to rituximab. Afutuzumab binds to FcγRIII using purified proteins with a higher affinity than rituximab. Afutuzumab and rituximab bind with similar affinity to overlapping epitopes on CD20.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.